semaglutide alcohol addiction Ozempic maker Novo Nordisk says it will study drug's effects on consumption but isn't focused on Semaglutide reduces binge-like alcohol drinking

Often, checking in with a healthcare provider is the best first step

Notably, while initially demonstrated in patients with T2DM, recent landmark trials have shown that semaglutide also significantly reduces primary cardiovascular endpoint events (including cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) in obese patients without diabetes, substantially expanding their potential cardioprotective applications

Pantelis A, Machairiotis N, Lapatsanis DP

Two RNA species that have attracted attention in this regard are lncRNAs and circRNAs

Glucagon-like peptide-1 (GLP-1) receptor agonists are injectable medications licensed for type 2 diabetes and, in some formulations, weight management